Previous close | 2.0000 |
Open | 2.0400 |
Bid | 2.0200 x 1000 |
Ask | 2.0500 x 1000 |
Day's range | 2.0000 - 2.1250 |
52-week range | 1.7000 - 30.5000 |
Volume | |
Avg. volume | 3,432,040 |
Market cap | 138.052M |
Beta (5Y monthly) | -0.93 |
PE ratio (TTM) | 2.90 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CAMBRIDGE, Mass., May 02, 2024--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") will report its first quarter 2024 financial results on Thursday, May 9, 2024. Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates.
CAMBRIDGE, Mass., April 10, 2024--Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial
CAMBRIDGE, Mass., April 08, 2024--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the Company will host a virtual webcast with management and Fumihiko Urano, MD, PhD, Principal Investigator of the HELIOS clinical trial and the Samuel E. Schechter Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at Washington University School of Medicine in St. Louis to discuss interim data from HELIOS, a Phase 2 trial of AMX0035 for the